New Products, Positive Clinical Trial Results, FDA Submissions and Stock Price Updates - Research Report on Pfizer, Cubist, Zoetis, Edwards Lifesciences, and C.R. Bard PR Newswire NEW YORK, November 28, 2013 NEW YORK, November 28, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Zoetis Inc. (NYSE: ZTS), Edwards Lifesciences Corp. (NYSE: EW) and C.R. Bard, Inc. (NYSE: BCR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Pfizer Inc. Research Report On November 25, 2013, Pfizer Inc. (Pfizer) introduced the Robitussin Maximum Strength Cough + Chest Congestion DM, the Company's new liquid-filled capsules that control cough on-the-go. According to the Company, the formulation not only uses the power of Maximum Strength Robitussin cough liquid, but is a convenient option for those hitting the road or boarding a plane during the holiday season. Pfizer also said that families can track when cough activity spikes in their local area through the Robitussin COUGHCAST tool, available on the Robitussin website. As per Pfizer, the tool can let people know when cough is most likely to strike, so they can be prepared to effectively treat their symptoms. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/d702_PFE -- Cubist Pharmaceuticals Inc. Research Report On November 25, 2013, Cubist Pharmaceuticals Inc. (Cubist) announced top-line results from the Company's pivotal Phase 3 clinical trial of its antibiotic candidate ceftolozane/tazobactam in complicated urinary tract infections (cUTI). Cubist said that ceftolozane/tazobactam met its primary endpoint of statistical non-inferiority compared to lefloxacin (10% inferiority margin). Cubist added that the primary endpoint is a composite of microbiological eradication and clinical cure rate (composite cure rate) at 5-9 days after end therapy (Test of Cure visit). Further, Cubist said that the 95% confidence interval around the treatment difference had lower and upper bounds of 2.3% and 14.6% respectively, favoring ceftolozane/tazobactam. In addition, the Company said that ceftolozane/tazobactam is being developed for the potential treatment of Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP), and expects to initiate a pivotal Phase 3 trial to assess the safety and efficacy of the same (at a dose of 3 g every 8 hours) in this indication during H1 2014. The Full Research Report on Cubist Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/92f2_CBST -- Zoetis Inc. Research Report On November 25, 2013, Zoetis Inc.'s stock declined 0.22%, ending the day at $31.29. Over the previous three trading sessions, shares of Zoetis declined 0.26% compared to the S&P 500 which gained 1.19% during the same period. The Full Research Report on Zoetis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/7e25_ZTS -- Edwards Lifesciences Corp. Research Report On November 25, 2013, Edwards Lifesciences Corp.'s (Edwards Lifesciences) stock declined 0.17%, ending the day at $64.75. Over the previous three trading sessions, shares of Edwards Lifesciences gained 2.84% compared to the S&P 500 which gained 1.19% during the same period. The Full Research Report on Edwards Lifesciences Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/48b8_EW -- C.R. Bard, Inc. Research Report On November 25, 2013, C.R. Bard, Inc. (Bard) announced that the Company's Lutonix technology center submitted the final module of the pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) to support approval for the Lutonix Drug-Coated PTA Dilatation Catheter (DCB). According to the Company, the Lutonix DCB is being clinically evaluated in the global, multicenter LEVANT 2 randomized clinical trial. The Company added that the purpose of this pivotal investigational device exemption (IDE) trial is to compare the safety and efficacy of the Lutonix DCB to standard angioplasty balloons for the treatment of peripheral arterial disease (PAD) in superficial femoral (SFA) and popliteal arteries. Timothy M. Ring, Chairman and CEO of Bard, said, "This submission marks a key milestone in our drug-coated balloon program, which continues to progress as expected. We look forward to interfacing with the FDA for the purpose of making this important technology available to U.S. patients." The Full Research Report on C.R. Bard, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/141e_BCR ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Icahn Takes 8.48% Stake in Hertz; May Seek Talks, Board Seat
New Products, Positive Clinical Trial Results, FDA Submissions and Stock Price Updates - Research Report on Pfizer, Cubist,
Press spacebar to pause and continue. Press esc to stop.